157 related articles for article (PubMed ID: 24258970)
1. Novel insights/translational implication from the emerging biology of melanoma.
Ribas A
Methods Mol Biol; 2014; 1102():3-9. PubMed ID: 24258970
[TBL] [Abstract][Full Text] [Related]
2. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough therapies in melanoma.
Lianos GD; Mangano A; Rausei S; Roukos DH
Future Oncol; 2014 Apr; 10(5):781-4. PubMed ID: 24799059
[No Abstract] [Full Text] [Related]
5. Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.
Vella LJ; Andrews MC; Behren A; Cebon J; Woods K
Expert Rev Clin Immunol; 2014 Aug; 10(8):1107-23. PubMed ID: 24939732
[TBL] [Abstract][Full Text] [Related]
6. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
7. Translational research in melanoma.
Ray M; Farma JM; Hsu C
Surg Oncol Clin N Am; 2013 Oct; 22(4):785-804. PubMed ID: 24012399
[TBL] [Abstract][Full Text] [Related]
8. Therapy for metastatic melanoma: an overview and update.
Boyle GM
Expert Rev Anticancer Ther; 2011 May; 11(5):725-37. PubMed ID: 21554048
[TBL] [Abstract][Full Text] [Related]
9. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
Lau PK; Ascierto PA; McArthur G
Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
[TBL] [Abstract][Full Text] [Related]
10. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
11. Emerging clinical issues in melanoma in the molecularly targeted era.
Sullivan RJ; Atkins MB
Methods Mol Biol; 2014; 1102():11-26. PubMed ID: 24258971
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for melanoma.
Katipamula R; Markovic SN
Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell vaccination as a treatment modality for melanoma.
Eubel J; Enk AH
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trial of local immunomodulation with DNCB in cases of advanced melanoma of the skin].
Budzanowska E; Pawlicki M
Przegl Dermatol; 1988; 75(1):29-34. PubMed ID: 3290999
[No Abstract] [Full Text] [Related]
16. Successes and limitations of targeted cancer therapy in melanoma.
Romano E; Michielin O
Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988
[TBL] [Abstract][Full Text] [Related]
17. New approaches in metastatic melanoma: biological and molecular targeted therapies.
Lejeune FJ; Rimoldi D; Speiser D
Expert Rev Anticancer Ther; 2007 May; 7(5):701-13. PubMed ID: 17492933
[TBL] [Abstract][Full Text] [Related]
18. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
Gingrich AA; Kirane AR
Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
[TBL] [Abstract][Full Text] [Related]
19. [Contribution of B lymphocytes in acquired resistance to targeted therapies in metastatic melanoma].
Fourneaux C; Dubois B
Med Sci (Paris); 2018 Oct; 34(10):875-878. PubMed ID: 30451659
[No Abstract] [Full Text] [Related]
20. [New treatments for metastatic melanoma: a first hope].
Robert C; Mateus C
Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
[No Abstract] [Full Text] [Related]
[Next] [New Search]
